TBThomas W. Barber

Thomas W. Barber

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thomas W. Barber has a total of 93 co-authors. Here are the top co-authors by number of shared publications:

  • Victor Kalff

    Department of Nuclear Medicine & PET, The Alfred Hospital, Melbourne, 3004, Australia

    5 shared publications
  • Martin H. Cherk

    The Department of Nuclear Medicine and PET, Alfred Health, Melbourne, VIC, Australia

    4 shared publications
  • Rodney John Hicks

    University of Melbourne 6 Department of Medicine, St Vincent’s Hospital Fitzroy, Australia

    4 shared publications
  • Kenneth S. K. Yap

    Department of Nuclear Medicine & PET, The Alfred Hospital, Melbourne, 3004, Australia

    3 shared publications
  • Michael S. Hofman

    Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia

    3 shared publications
  • Andre La Gerche

    St Vincent's Institute of Medical Research

    2 shared publications

Latest Publications

  • Open Access

    A Critical Review of Clinical Factors and Tools for Predicting Chimeric Antigen Receptor T-Cell Toxicities

    by Jian Li, Mark R Dowling, Miriam Wronski, Christina Kazzi, Salvatore Fiorenza, Martin Cherk, Shu-Min Wong, Shafqat Inam, Thomas W Barber, Mastura Monif, et al.

  • Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy

    by Thomas W. Barber, Aviral Singh, Harshad R. Kulkarni, Karin Niepsch, Baki Billah, Richard P. Baum

    177Lu-labelled prostate-specific membrane antigen (PSMA) radioligand therapy using PSMA-617 and PSMA-I&T ligands (177Lu-PRLT) is an emerging treatment in metastatic castration resistant prostate cancer (mCRPC). This retrospective study evaluates clinical outcomes of 177Lu-PRLT in taxane chemotherapy pretreated (T-pretreated) and taxane chemotherapy naïve (T-naïve) patients with mCRPC. Materials and Methods: A retrospective analysis was performed on 167 patients with mCRPC who underwent 177Lu-PRLT between March-2013 and December-2016. Patients were classified as either T-pretreated or T-naïve depending on whether they had received taxane-based chemotherapy prior to 177Lu-PRLT. Clinical outcome for T-pretreated and T-naïve patients was assessed by overall survival (OS), radiographic progression free survival (rPFS) and prostate-specific antigen (PSA) response rate. Univariate and multivariable analyses were performed for both T-pretreated and T-naïve patients to determine predictors of outcome. Toxicity was categorized by the common toxicity criteria for adverse events (version 4.03) and compared between the two groups. Results: Of the 167 patients treated with 177Lu-PRLT, 83 were T-pretreated and 84 were T-naïve. At baseline, T-pretreated patients had overall poorer performance status, a higher prevalence of bone metastases, higher PSA levels, lower hemoglobin levels and higher ALP levels compared to T-naïve patients. Median OS was 10.7 months for T-pretreated patients and 27.1 months for T-naïve patients (pP = 0.003). PSA response assessment was evaluable in 132 patients and seen in 25/62 (40%) T-pretreated patients and 40/70 (57%) T-naïve patients (P = 0.054). Significant determinates of inferior OS in multivariable analysis for T-pretreated patients were poorer performance status, lower cumulative administered activity and lower baseline hemoglobin. Higher baseline ALP was the only significant determinate of inferior OS in multivariable analysis for T-naïve patients. Overall 177Lu-PRLT was safe with minimal adverse effects evident during follow-up in both T-pretreated and T-naïve patients. Conclusion: 177Lu-PRLT is a promising therapy in mCRPC with encouraging outcomes and minimal associated toxicity seen in both T-naïve and T-pretreated patients.


  • Correction to: Pioglitazone reduces cold-induced brown fat glucose uptake despite induction of browning in cultured human adipocytes: a randomised, controlled trial in humans

    by Rebecca K. C. Loh, Melissa F. Formosa, Nina Eikelis, David A. Bertovic, Mitchell J. Anderson, Shane A. Barwood, Shane Nanayakkara, Neale D. Cohen, Andre La Gerche, Anne T. Reutens, et al.

    The baseline insulin data given in Table 1 for the placebo group were incorrectly reported as 51 ± 10 pmol/l instead of 48 ± 10 pmol/l. This mistake also impacts on data reported in Table 4.


  • Pioglitazone reduces cold-induced brown fat glucose uptake despite induction of browning in cultured human adipocytes: a randomised, controlled trial in humans

    by Rebecca K. C. Loh, Melissa F. Formosa, Nina Eikelis, David A. Bertovic, Mitchell J. Anderson, Shane A. Barwood, Shane Nanayakkara, Neale D. Cohen, Andre La Gerche, Anne T. Reutens, et al.

    Increasing brown adipose tissue (BAT) activity is a possible therapeutic strategy to increase energy expenditure and glucose and lipid clearance to ameliorate obesity and associated comorbidities. The thiazolidinedione (TZD) class of glucose-lowering drugs increase BAT browning in preclinical experimental models but whether these actions extend to humans in vivo is unknown. The aim of this study was to determine the effect of pioglitazone treatment on adipocyte browning and adaptive thermogenesis in humans.


  • Predictive performance of different kidney function estimation equations in lung transplant patients

    by Dov A Degen, Jyotsna Janardan, Katherine A Barraclough, Hans G Schneider, Thomas Barber, Howard Barton, Gregory Snell, Bronwyn Levvey, Rowan G Walker


  • Open Access

    Plasma Macrophage Migration Inhibitor Factor Is Elevated in Response to Myocardial Ischemia

    by Fenling Fan, Lu Fang, Xiao‐Lei Moore, Xuegang Xie, Xiao‐Jun Du, David A. White, Jessica O'BRien, Helen Thomson, Jun Wang, Hans G. Schneider, et al.

    Background: Macrophage migration inhibitory factor ( MIF ) is a key regulator of inflammatory responses, including in the heart. Plasma MIF is elevated early in the course of acute myocardial infarction. In this study, we hypothesized that plasma MIF may also be increased in acute myocardial ischemia. Methods and Results: Patients undergoing cardiac stress test (stress nuclear myocardial perfusion scan or stress echocardiography) were recruited. Twenty‐two patients had a stress test indicative of myocardial ischemia and were compared with 62 patients who had a negative stress test. Plasma MIF was measured by ELISA before and after the stress test. MIF was also measured in patients with peripheral arterial occlusive disease before and after exercise causing claudication. Gene and protein expression of MIF was measured in mouse cardiac and skeletal muscle tissue by real‐time polymerase chain reaction and western blot, respectively. Plasma MIF was elevated at 5 and 15 minutes after stress (relative to before stress) in patients with a positive test, compared with those with a negative test. In contrast, high‐sensitivity troponin T and C‐reactive protein were not altered after stress in either group. MIF was not altered after exercise in PAOD patients, despite the occurrence of claudication, suggesting that plasma MIF is not a marker for skeletal muscle ischemia. This may be explained by a lower gene and protein expression of MIF in skeletal muscle than the heart. Conclusions: Our results suggest that plasma MIF is an early marker for acute myocardial ischemia.


  • Open Access

    Correlation of clinical outcomes with bremsstrahlung and Y-90 PET/CT imaging findings following Y-90 radiosynoviorthesis: a prospective study

    by Thomas W. Barber, Martin H. Cherk, Anne Powell, Kenneth S. K. Yap, Baki Billah, Victor Kalff

    It is unclear how to predict which patients will respond to Y-90 radiosynoviorthesis. The aim of this study is to correlate clinical outcomes following Y-90 radiosynoviorthesis with bremsstrahlung and Y-90 PET/CT imaging findings. Fifty-one joints underwent bremsstrahlung planar and Y-90 PET/CT imaging following Y-90 radiosynoviorthesis. The Y-90 distribution pattern on bremsstrahlung planar imaging was classified as diffuse or non-diffuse and compared with the intra or extra-articular location of activity on Y-90 PET/CT. Treatment response was assessed by patients and clinicians at 6 months. In patients who underwent bremsstrahlung SPECT, side-by-side comparison with PET was performed with image quality/resolution scored using a five-point-scale. Bremsstrahlung planar images were classified as diffuse in 33/51 (65 %) and non-diffuse in 18/51 (35 %) scans. There was no association between treatment response and the bremsstrahlung planar imaging pattern. PET/CT confirmed an intra-articular location in all 33/33 (100 %) diffuse scans and an extra-articular location in 3/18 (17 %) non-diffuse scans. Of the three joints with extra-articular activity, none had any treatment response. Excluding these three joints, there remained no association between the bremsstrahlung planar imaging pattern and treatment response. Of the 42 joints imaged with SPECT, PET image quality/resolution was classified as superior in 40 (95 %). In one patient with extra-articular activity on PET/CT, SPECT/CT was unable to definitively localise the activity to the intra or extra-articular space. The distribution pattern on bremsstrahlung planar imaging did not correlate with clinical outcome following Y-90 radiosynoviorthesis in our study population. However, in patients with non-diffuse planar imaging patterns, Y-90 PET/CT should be considered to exclude extra-articular activity with PET providing superior image quality compared to SPECT.


  • Ga‐68 octreotate PET/CT and Tc‐99m heat‐denatured red blood cell SPECT/CT imaging of an intrapancreatic accessory spleen

    by Thomas W Barber, Andrew Dixon, Marty Smith, Kenneth S K Yap, Victor Kalff

    Summary: Intrapancreatic accessory spleens are relatively uncommon and can be difficult to distinguish from neuroendocrine tumours on CT, MRI and somatostatin receptor scintigraphy. We present the case of a 26‐year‐old woman with an incidentally diagnosed pancreatic lesion confirmed to be an intrapancreatic accessory spleen on Tc‐99m heat‐denatured red blood cell single photon emission computed tomography/CT.


  • The prevalence of thyroglossal tract thyroid tissue on SPECT/CT following 131I ablation therapy after total thyroidectomy for thyroid cancer

    by Thomas W. Barber, Martin H. Cherk, Duncan J. Topliss, Jonathan W. Serpell, Kenneth S. K. Yap, Michael Bailey, Victor Kalff

    To determine the prevalence of thyroglossal tract thyroid tissue on SPECT/CT and to assess the contribution of this tissue to total neck radioactive iodine (RAI) activity in patients given (131) I ablation therapy after total thyroidectomy for thyroid cancer. Eighty-three consecutive patients with thyroid cancer treated with total thyroidectomy underwent whole-body planar and SPECT/CT imaging of the neck following initial RAI ablation. On SPECT/CT, thyroglossal tract thyroid tissue was defined as RAI in the anterior neck, superior to the thyroid bed in close proximity to the midline without evidence of localization to lymph nodes. Quantification was performed using region of interest analysis on planar imaging following localization on SPECT/CT. SPECT/CT, and planar images were classified by two reviewers as positive, negative or equivocal with interobserver agreement quantified using a Kappa score. Disagreement was resolved using a third reviewer. Thyroglossal tract thyroid tissue was present in 39/83 (47%; 95%CI: 36-58%) patients on SPECT/CT. In these 39 patients, this tissue contributed to a significant amount of total neck activity (median = 50%; IQR 19-74%). Interobserver agreement for the presence of thyroglossal tract thyroid tissue was substantial on SPECT/CT (Kappa = 0.73) and fair on planar imaging (Kappa = 0.31). Thyroglossal tract thyroid tissue was present in one half of our study population and contributed to a significant amount of total neck RAI activity. Given the high prevalence of this tissue, our results suggest that total neck RAI activity on planar imaging may not be suitable to assess the completeness of thyroid bed surgery.


  • Comparison of positron emission tomography/CT and bremsstrahlung imaging following Y-90 radiation synovectomy

    by Thomas W. Barber, Kenneth S. K. Yap, Martin H. Cherk, Anne Powell, Victor Kalff

    The aim of this study is to compare the results of positron emission tomography (PET)/CT with bremsstrahlung imaging following Y‐90 radiation synovectomy.